What this quiz covers
This quiz focuses on Two Hit Hypothesis, giving you a quick way to practice the rules, question types, and explanations that matter most for Genetics.
A pedigree for a family with Li-Fraumeni syndrome (TP53 mutation) shows a clear autosomal dominant pattern of cancer predisposition. However, at the cellular level, TP53 is a recessive tumor suppressor gene. How is this apparent contradiction explained by the two-hit hypothesis?
Genetics Quiz
Practice Two Hit Hypothesis in Genetics with focused quiz questions that help you check what you know, review explanations, and build confidence with test-style prompts.
This quiz focuses on Two Hit Hypothesis, giving you a quick way to practice the rules, question types, and explanations that matter most for Genetics.
Try each quiz question before looking at the correct answer. Use the explanations to review missed ideas, then come back to similar questions until the pattern feels familiar.
A pedigree for a family with Li-Fraumeni syndrome (TP53 mutation) shows a clear autosomal dominant pattern of cancer predisposition. However, at the cellular level, TP53 is a recessive tumor suppressor gene. How is this apparent contradiction explained by the two-hit hypothesis?
Explanation: The key distinction is between the genetics of the predisposition and the genetics of the cancer cell itself. The predisposition is inherited as a dominant trait because inheriting one mutant allele makes cancer highly probable (high penetrance). However, a cell only becomes cancerous after the second, wild-type allele is also lost or mutated (the 'second hit'), meaning the gene is recessive at the cellular level.
Tumor suppressor genes are sometimes classified as 'gatekeepers' or 'caretakers'. The two-hit hypothesis was originally developed based on RB1, a classic 'gatekeeper'. How does the function of a gatekeeper gene directly relate to the two-hit model?
Explanation: When you encounter questions about tumor suppressor genes, focus on understanding the fundamental difference between "gatekeepers" and "caretakers" and how this relates to cancer development mechanisms. Gatekeeper genes like RB1 function as direct controllers of cell division—they act as molecular brakes that either halt the cell cycle at checkpoints or trigger apoptosis when cells become damaged or abnormal. The two-hit hypothesis perfectly describes how these genes work: since you inherit two copies of each gene, losing just one copy still leaves the other functional copy to maintain control over cell division. However, when both copies are lost or mutated (the "two hits"), the cell loses this critical brake system entirely, allowing uncontrolled proliferation that can lead to cancer. Option A confuses gatekeepers with caretakers—caretaker genes are the ones responsible for DNA repair. Option B describes angiogenesis factors, not tumor suppressors. Option C incorrectly suggests a dominant-negative effect, which would actually support a one-hit model rather than the two-hit hypothesis that characterizes gatekeeper genes. Option D correctly identifies that gatekeepers directly control cell cycle progression and apoptosis, and that losing both functional copies removes the primary mechanism preventing uncontrolled cell division. Remember this key distinction: gatekeepers are the "direct brake pedal" on cell division, while caretakers are the "maintenance crew" that fixes DNA damage. The two-hit model applies to gatekeepers because you need to lose both brakes before the car (cell) goes out of control.
Understanding the two-hit basis of cancers like those caused by BRCA1/2 mutations has led to targeted therapies. What is the therapeutic principle behind using PARP inhibitors in a patient with a hereditary BRCA1/2-mutant ovarian cancer?
Explanation: This question tests your understanding of synthetic lethality—a powerful concept where the combination of two genetic defects is lethal to a cell, even though each defect alone might be survivable. PARP inhibitors work through synthetic lethality in BRCA-deficient tumors. Here's the logic: BRCA1/2 proteins are essential for homologous recombination, a high-fidelity DNA repair pathway. In hereditary BRCA cancers, tumor cells have lost both BRCA alleles (following Knudson's two-hit hypothesis), leaving them unable to perform this crucial repair function. These cells compensate by relying heavily on alternative repair pathways, including base excision repair, which depends on the PARP enzyme. When you inhibit PARP in BRCA-deficient cells, you eliminate their backup repair mechanism, causing accumulation of DNA damage and cell death. Normal cells, which still have functional BRCA proteins, can survive PARP inhibition because they retain homologous recombination capability. Choice A correctly describes this synthetic lethal relationship. Choice B is wrong because PARP inhibitors don't restore BRCA function—they're enzyme inhibitors, not gene therapy. Choice C misunderstands the mechanism; the germline mutation alone (first hit) doesn't make cells hypersensitive—it's the complete loss of BRCA function in tumor cells that creates vulnerability. Choice D incorrectly suggests PARP inhibitors bind to BRCA proteins; they actually inhibit the PARP enzyme directly. Remember: synthetic lethality exploits vulnerabilities created by cancer-specific genetic defects, allowing targeted therapy that preferentially kills tumor cells while sparing normal tissue.
A patient is diagnosed with a tumor found to have biallelic inactivation of a known tumor suppressor gene, TSG-X. Surprisingly, the patient has no family history of cancer, and the tumor appeared late in life. If this case adheres to the two-hit hypothesis, what can be inferred about the origin of the two 'hits'?
Explanation: When you encounter a tumor suppressor gene question, focus on Knudson's two-hit hypothesis: both copies of a tumor suppressor gene must be inactivated for cancer to develop. The key is determining whether hits are germline (inherited) or somatic (acquired during lifetime). The clinical presentation provides crucial clues. This patient has no family history of cancer and developed the tumor late in life. If either hit were germline, you'd expect earlier onset and often a family history, since germline mutations are present in every cell from birth, making the second hit more likely to occur sooner. Since both hits occurred somatically in the same cell lineage, this explains the late onset - it takes time for two independent mutational events to occur in the same cell. The lack of family history makes sense because neither parent carried a germline mutation to pass down. Option B is incorrect because a germline first hit, even with low penetrance, would likely manifest earlier and show some family pattern. Option C describes mosaicism, but early developmental mutations affecting multiple cells would still likely cause earlier onset than pure somatic events. Option D suggests an inherited mutation with modifier gene protection, but this doesn't align with the complete absence of family history. Study tip: For tumor suppressor genetics questions, always correlate the clinical presentation with mutation timing. Germline hits = early onset + family history. Pure somatic hits = later onset + no family history. This pattern recognition will serve you well on genetics exams.
A child develops a unilateral retinoblastoma at age 4. Genetic testing of their blood shows no RB1 mutation, but analysis of the tumor reveals loss of heterozygosity across the RB1 locus and a single point mutation. What is the most likely classification of this case?
Explanation: The absence of the mutation in blood DNA indicates it is not a germline event. The presence of two 'hits' (a mutation and LOH) only in the tumor is the definition of a sporadic cancer according to the two-hit hypothesis. Later onset (age 4) and unilateral presentation are also characteristic of sporadic cases. While somatic mosaicism (C) is a possibility, the most straightforward and common explanation is a classic sporadic tumor.
Some TP53 mutations exert a dominant-negative effect, where the mutant p53 protein tetramerizes with and inactivates the wild-type p53 protein. How does this specific mechanism modify the classic two-hit hypothesis?
Explanation: A dominant-negative mutation is a significant modification to the simple two-hit loss-of-function model. The first hit does more than just remove one functional copy; it actively poisons the protein produced from the remaining wild-type allele. This means a single heterozygous mutation can severely impair the tumor suppressor pathway, behaving phenotypically as if two hits have occurred, thus accelerating tumorigenesis without necessarily requiring a physical loss of the second allele.
A genetic counselor explains to a family that hereditary retinoblastoma follows the two-hit hypothesis. Which statement most accurately differentiates the genetic events in hereditary versus sporadic forms of the disease according to this hypothesis?
Explanation: The two-hit hypothesis posits that for tumor suppressor genes like RB1, both alleles must be inactivated. In hereditary cases, the 'first hit' is a germline mutation present in all cells, and the 'second hit' is a somatic mutation in the remaining wild-type allele. In sporadic cases, both 'hits' are separate somatic mutation events that must occur in the same cell.
While most tumor suppressor genes (TSGs) follow the two-hit model, some are known to be haploinsufficient. How does cancer development involving a haploinsufficient TSG differ from the classic two-hit model?
Explanation: Haploinsufficiency means that a single functional copy of a gene is not enough to maintain the normal state. For a haploinsufficient TSG, losing one allele (the first hit) already creates a pro-tumorigenic cellular environment because 50% of the protein is not enough to perform the tumor-suppressing function adequately. A second hit may still occur and often does, but the initial loss is not silent as it is in the classic model.
Assume the somatic mutation rate for a tumor suppressor gene is 10−6 per cell generation and there are 107 susceptible cells. Which calculation best explains why hereditary cancer (one germline hit) is far more common than sporadic cancer (two somatic hits)?
Explanation: This question requires applying probabilistic reasoning. In the hereditary case, the probability of a second hit is the rate of one mutation multiplied by the large number of target cells. Since 107×10−6=10, it is statistically almost certain to happen. In the sporadic case, the probability of two independent mutations occurring in the same cell is proportional to the square of the single-mutation rate, (10−6)2=10−12, an exceedingly rare event, even when considering the total number of cells.
A patient with hereditary retinoblastoma is heterozygous for a specific missense mutation in exon 12 of the RB1 gene. Analysis of their tumor DNA reveals that the cells are homozygous for this exact same missense mutation. Which of the following mechanisms for the 'second hit' most directly explains this specific outcome?
Explanation: For a cell to become homozygous for a pre-existing mutation, the genetic information from the mutant chromosome must be copied over to the wild-type chromosome, or segregation must result in two mutant copies. Mitotic recombination can lead to a daughter cell that is homozygous for all genes distal to the crossover point. Nondisjunction or deletion (B and D) would result in hemizygosity (only one copy of the gene), not homozygosity. A new identical mutation (A) is theoretically possible but statistically far less likely than mitotic recombination or gene conversion.
The progression of sporadic colorectal cancer is often depicted as a multi-step process involving sequential mutations (e.g., in APC, KRAS, TP53). How does this model relate to the original two-hit hypothesis?
Explanation: The multi-step model of colon cancer is not a rejection of the two-hit hypothesis but an expansion of it. The initial event is often the biallelic inactivation of the APC gene (satisfying the two-hit requirement for that gatekeeper). This initiates the polyp, but for progression to carcinoma, additional mutations are needed, including the activation of an oncogene (KRAS) and the inactivation of another tumor suppressor (TP53), which would also require two hits.
A researcher analyzes tumor tissue from a patient with familial adenomatous polyposis (FAP) who is known to be heterozygous for a germline nonsense mutation in the APC gene. What molecular finding in the tumor cells' APC locus would provide the strongest evidence for a 'second hit' via loss of heterozygosity (LOH)?
Explanation: Loss of heterozygosity (LOH) is a common mechanism for the second hit. In this scenario, the patient's normal cells are heterozygous (mutant/wild-type). If the tumor cell has lost the chromosome segment containing the wild-type allele, only the mutant allele will remain. This finding of homozygosity or hemizygosity for the mutant allele in the tumor, compared to heterozygosity in normal tissue, is the hallmark of LOH.
A patient with hereditary retinoblastoma is heterozygous for a specific missense mutation in exon 12 of the RB1 gene. Analysis of their tumor DNA reveals that the cells are homozygous for this exact same missense mutation. Which of the following mechanisms for the 'second hit' most directly explains this specific outcome?
Explanation: For a cell to become homozygous for a pre-existing mutation, the genetic information from the mutant chromosome must be copied over to the wild-type chromosome, or segregation must result in two mutant copies. Mitotic recombination can lead to a daughter cell that is homozygous for all genes distal to the crossover point. Nondisjunction or deletion (B and D) would result in hemizygosity (only one copy of the gene), not homozygosity. A new identical mutation (A) is theoretically possible but statistically far less likely than mitotic recombination or gene conversion.
While most tumor suppressor genes (TSGs) follow the two-hit model, some are known to be haploinsufficient. How does cancer development involving a haploinsufficient TSG differ from the classic two-hit model?
Explanation: Haploinsufficiency means that a single functional copy of a gene is not enough to maintain the normal state. For a haploinsufficient TSG, losing one allele (the first hit) already creates a pro-tumorigenic cellular environment because 50% of the protein is not enough to perform the tumor-suppressing function adequately. A second hit may still occur and often does, but the initial loss is not silent as it is in the classic model.
A large study analyzes tumor DNA from patients with sporadic bladder cancer. If the tumor suppressor gene BLS1 is a key driver of this cancer and follows the two-hit hypothesis, what genetic signature would be expected in the tumor cells of affected individuals?
Explanation: For a sporadic cancer driven by a TSG, the two-hit hypothesis predicts that both hits must be somatic and must occur in the tumor lineage. Therefore, the tumor cells would show biallelic (both alleles) inactivation of BLS1, while the patient's normal, germline DNA would have two functional copies. This inactivation can occur through two separate mutations or, more commonly, one mutation followed by loss of the other allele (LOH).
Tumor suppressor genes are sometimes classified as 'gatekeepers' or 'caretakers'. The two-hit hypothesis was originally developed based on RB1, a classic 'gatekeeper'. How does the function of a gatekeeper gene directly relate to the two-hit model?
Explanation: When you encounter questions about tumor suppressor genes, focus on understanding the fundamental difference between "gatekeepers" and "caretakers" and how this relates to cancer development mechanisms. Gatekeeper genes like RB1 function as direct controllers of cell division—they act as molecular brakes that either halt the cell cycle at checkpoints or trigger apoptosis when cells become damaged or abnormal. The two-hit hypothesis perfectly describes how these genes work: since you inherit two copies of each gene, losing just one copy still leaves the other functional copy to maintain control over cell division. However, when both copies are lost or mutated (the "two hits"), the cell loses this critical brake system entirely, allowing uncontrolled proliferation that can lead to cancer. Option A confuses gatekeepers with caretakers—caretaker genes are the ones responsible for DNA repair. Option B describes angiogenesis factors, not tumor suppressors. Option C incorrectly suggests a dominant-negative effect, which would actually support a one-hit model rather than the two-hit hypothesis that characterizes gatekeeper genes. Option D correctly identifies that gatekeepers directly control cell cycle progression and apoptosis, and that losing both functional copies removes the primary mechanism preventing uncontrolled cell division. Remember this key distinction: gatekeepers are the "direct brake pedal" on cell division, while caretakers are the "maintenance crew" that fixes DNA damage. The two-hit model applies to gatekeepers because you need to lose both brakes before the car (cell) goes out of control.
Assume the somatic mutation rate for a tumor suppressor gene is 10−6 per cell generation and there are 107 susceptible cells. Which calculation best explains why hereditary cancer (one germline hit) is far more common than sporadic cancer (two somatic hits)?
Explanation: This question requires applying probabilistic reasoning. In the hereditary case, the probability of a second hit is the rate of one mutation multiplied by the large number of target cells. Since 107×10−6=10, it is statistically almost certain to happen. In the sporadic case, the probability of two independent mutations occurring in the same cell is proportional to the square of the single-mutation rate, (10−6)2=10−12, an exceedingly rare event, even when considering the total number of cells.
Which of the following experimental findings for a newly studied cancer-associated gene would pose the most direct challenge to the applicability of the classic two-hit hypothesis?
Explanation: When evaluating challenges to the classic two-hit hypothesis, you need to understand its core prediction: tumor suppressor genes require inactivation of both alleles to lose function and promote cancer. The first hit (often germline) inactivates one copy, while the second hit eliminates the remaining functional allele. Answer D poses the most direct challenge because it contradicts the fundamental mechanism. If tumor cells "consistently show high expression of the remaining wild-type allele," this means the second allele is not only intact but actively producing protein. This directly violates the two-hit model, which requires both copies to be nonfunctional for cancer to develop. Answer A is actually consistent with the two-hit hypothesis. Epigenetic silencing effectively inactivates genes just like DNA mutations do—the mechanism of the second hit doesn't matter, only that it occurs. Answer B also supports the model, as autosomal recessive inheritance patterns align perfectly with needing two defective alleles for disease manifestation. Answer C describes variable penetrance or expressivity, which is common in cancer genetics and doesn't challenge the core two-hit mechanism—it just reflects the complexity of cancer development beyond the initial tumor suppressor loss. The key strategy here is distinguishing between findings that modify details of the two-hit hypothesis versus those that fundamentally contradict it. Look for scenarios where both alleles should be inactive according to the model, but experimental evidence shows otherwise.
Some TP53 mutations exert a dominant-negative effect, where the mutant p53 protein tetramerizes with and inactivates the wild-type p53 protein. How does this specific mechanism modify the classic two-hit hypothesis?
Explanation: A dominant-negative mutation is a significant modification to the simple two-hit loss-of-function model. The first hit does more than just remove one functional copy; it actively poisons the protein produced from the remaining wild-type allele. This means a single heterozygous mutation can severely impair the tumor suppressor pathway, behaving phenotypically as if two hits have occurred, thus accelerating tumorigenesis without necessarily requiring a physical loss of the second allele.
A patient is diagnosed with a tumor found to have biallelic inactivation of a known tumor suppressor gene, TSG-X. Surprisingly, the patient has no family history of cancer, and the tumor appeared late in life. If this case adheres to the two-hit hypothesis, what can be inferred about the origin of the two 'hits'?
Explanation: When you encounter a tumor suppressor gene question, focus on Knudson's two-hit hypothesis: both copies of a tumor suppressor gene must be inactivated for cancer to develop. The key is determining whether hits are germline (inherited) or somatic (acquired during lifetime). The clinical presentation provides crucial clues. This patient has no family history of cancer and developed the tumor late in life. If either hit were germline, you'd expect earlier onset and often a family history, since germline mutations are present in every cell from birth, making the second hit more likely to occur sooner. Since both hits occurred somatically in the same cell lineage, this explains the late onset - it takes time for two independent mutational events to occur in the same cell. The lack of family history makes sense because neither parent carried a germline mutation to pass down. Option B is incorrect because a germline first hit, even with low penetrance, would likely manifest earlier and show some family pattern. Option C describes mosaicism, but early developmental mutations affecting multiple cells would still likely cause earlier onset than pure somatic events. Option D suggests an inherited mutation with modifier gene protection, but this doesn't align with the complete absence of family history. Study tip: For tumor suppressor genetics questions, always correlate the clinical presentation with mutation timing. Germline hits = early onset + family history. Pure somatic hits = later onset + no family history. This pattern recognition will serve you well on genetics exams.